Search

Search Constraints

You searched for: Author/Creator Taylor, M H

Search Results

1. 363OTreatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC). (24th November 2019)

2. 994OLenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC). (1st October 2019)